Pipeline

Resalis is pursuing a dual indications strategy in obesity and fatty liver disease with first- and second-generation miR-22 inhibitory drug candidates having durable, disease-modifying therapeutic impact. Our lead candidate, RES-010 is being developed for obesity and metabolic associated fatty liver disease (MAFLD) and its progressive disease state, metabolic associated steatohepatitis (MASH).